Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$12.27 +1.5%	$9.08	$5.51 ▼ $12.48	$1.59B	1.23	2.79 million shs	2.26 million shs
CDTX Cidara Therapeutics	$65.21 +2.6%	$49.71	$10.14 ▼ $66.94	$1.61B	1.18	503,380 shs	632,028 shs
GOSS Gossamer Bio	$1.96	$1.58	$0.66 ▼ $2.23	$445.67M	1.96	3.25 million shs	1.73 million shs
TVTX Travere Therapeutics	$18.82 +3.2%	$15.73	$8.46 ▼ $25.29	$1.63B	0.74	1.47 million shs	1.62 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	+0.67%	+5.77%	+34.48%	+47.62%	+116.28%
CDTX Cidara Therapeutics	+0.47%	+2.95%	+23.42%	+149.22%	+394.17%
GOSS Gossamer Bio	-0.51%	+12.64%	+35.17%	+88.46%	+137.00%
TVTX Travere Therapeutics	+1.00%	+7.81%	+11.29%	+8.51%	+113.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	2.8348 of 5 stars	1.5	3.0	0.0	2.9	2.5	3.1
CDTX Cidara Therapeutics	3.7437 of 5 stars	2.6	3.0	4.6	3.2	1.7	0.0
GOSS Gossamer Bio	3.8918 of 5 stars	3.5	1.0	4.7	3.1	1.7	0.0
TVTX Travere Therapeutics	2.6952 of 5 stars	3.4	3.0	0.0	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$12.00	-2.20% Downside
CDTX Cidara Therapeutics	3.11	Buy	$64.14	-1.64% Downside
GOSS Gossamer Bio	3.00	Buy	$8.50	333.67% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.21	71.17% Upside

Current Analyst Ratings Breakdown

Latest GOSS, CDTX, TVTX, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$59.00 ➝ $66.00
8/8/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $74.00
8/8/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $74.00
8/7/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $31.00
8/7/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$30.00 ➝ $32.00
8/6/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
8/1/2025	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $9.00
7/30/2025	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$260.11M	6.21	$0.31 per share	39.20	$2.55 per share	4.81
CDTX Cidara Therapeutics	$1.27M	1,302.15	N/A	N/A	$19.76 per share	3.30
GOSS Gossamer Bio	$114.70M	3.89	N/A	N/A	($0.20) per share	-9.80
TVTX Travere Therapeutics	$233.18M	7.19	N/A	N/A	$0.37 per share	50.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.43	28.54	21.91	N/A	23.31%	20.06%	13.81%	N/A
CDTX Cidara Therapeutics	-$169.83M	-$11.13	N/A	N/A	N/A	N/A	-50.81%	-42.46%	N/A
GOSS Gossamer Bio	-$56.53M	-$0.62	N/A	N/A	N/A	-344.81%	-1,774.72%	-46.73%	N/A
TVTX Travere Therapeutics	-$321.55M	-$2.04	N/A	N/A	N/A	-50.64%	-717.68%	-30.69%	10/30/2025 (Estimated)

Latest GOSS, CDTX, TVTX, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	-$1.65	+$0.22	-$1.65	N/A	N/A
8/6/2025	Q2 2025	TVTX Travere Therapeutics	-$0.28	-$0.14	+$0.14	-$0.14	$100.18 million	$94.84 million
8/5/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	-$0.17	+$0.01	-$0.17	$4.12 million	$11.49 million
7/31/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.17	$0.16	-$0.01	$0.16	$64.27 million	$70.01 million
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.18	5.23	4.63
CDTX Cidara Therapeutics	N/A	16.45	3.87
GOSS Gossamer Bio	6.70	4.40	4.40
TVTX Travere Therapeutics	9.50	2.00	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
CDTX Cidara Therapeutics	35.82%
GOSS Gossamer Bio	81.23%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
CDTX Cidara Therapeutics	3.89%
GOSS Gossamer Bio	6.70%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	131.63 million	115.57 million	Optionable
CDTX Cidara Therapeutics	90	25.36 million	24.37 million	No Data
GOSS Gossamer Bio	180	227.38 million	212.15 million	Optionable
TVTX Travere Therapeutics	460	89.14 million	85.40 million	Optionable

GOSS, CDTX, TVTX, and AUPH Headlines

Recent News About These Companies

Analysts Set Travere Therapeutics, Inc. (NASDAQ:TVTX) Price Target at $32.21

August 15 at 2:41 AM | americanbankingnews.com

Informed Momentum Co LLC Invests $2.69 Million in Travere Therapeutics, Inc. (NASDAQ:TVTX)

August 14 at 5:47 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Boosts Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

August 13 at 4:26 AM | marketbeat.com

TVTX FY2025 EPS Forecast Boosted by Cantor Fitzgerald

August 12 at 3:02 AM | americanbankingnews.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by Analysts

August 12 at 2:16 AM | marketbeat.com

Cantor Fitzgerald Issues Positive Outlook for TVTX Earnings

August 11, 2025 | marketbeat.com

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $31.00

August 10, 2025 | americanbankingnews.com

Wedbush Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock

August 10, 2025 | americanbankingnews.com

Travere Therapeutics price target raised to $32 from $30 at Wedbush

August 8, 2025 | finance.yahoo.com

Travere Therapeutics (NASDAQ:TVTX) Given New $31.00 Price Target at Scotiabank

August 8, 2025 | marketbeat.com

Wedbush Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $32.00

August 8, 2025 | marketbeat.com

Travere Therapeutics shares rise as Q2 results top expectations

August 7, 2025 | investing.com

Travere Therapeutics Reports Strong Q2 2025 Growth

August 7, 2025 | msn.com

Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Travere Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 6, 2025 | seekingalpha.com

Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

August 6, 2025 | zacks.com

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

August 6, 2025 | zacks.com

Earnings Preview: Travere Therapeutics

August 5, 2025 | benzinga.com

XTX Topco Ltd Has $935,000 Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

August 4, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Short Interest Update

August 2, 2025 | marketbeat.com

Travere Therapeutics (TVTX) Expected to Announce Earnings on Thursday

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, CDTX, TVTX, and AUPH Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$12.27 +0.18 (+1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$12.36 +0.10 (+0.77%)

As of 07:59 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Cidara Therapeutics NASDAQ:CDTX

$65.21 +1.66 (+2.61%)

Closing price 04:00 PM Eastern

Extended Trading

$66.42 +1.21 (+1.86%)

As of 07:46 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Gossamer Bio NASDAQ:GOSS

$1.96 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.95 -0.01 (-0.51%)

As of 07:44 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Travere Therapeutics NASDAQ:TVTX

$18.82 +0.59 (+3.24%)

Closing price 04:00 PM Eastern

Extended Trading

$18.82 0.00 (0.00%)

As of 05:00 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time